vTv Therapeutics regains Nasdaq MVLS compliance; listing continues

vTv Therapeutics Inc.

Nasdaq notified vTv Therapeutics on March 25, 2024 that it regained compliance with the $35M MVLS minimum.
Common stock ticker VTVT will continue listing on the Nasdaq Capital Market.
No further deficiency actions required; prior MVLS concern resolved.

item 8.01

vTv Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001641489-24-000020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.